Search results for "Recurrent thrombosis"

showing 3 items of 3 documents

Incidence and severity of postthrombotic syndrome after iliofemoral thrombosis - results of the Iliaca-PTS - Registry.

2021

Summary: Background: Deep venous thrombosis (DVT) and in particular, iliofemoral thrombosis (IFT) can lead to recurrent thrombosis and postthrombotic syndrome (PTS). Data on the prevalence, predictors and outcome of IFT are scarce. Patients and methods: We retrospectively searched our database of outpatients who had presented with DVT and IFT including the iliac veins from 2014 until 2017. In addition, we performed a prospective registry in a subgroup of patients with IFT. These patients received duplex ultrasound, magnetic resonance venography and measurement of symptom-free walking distance using a standardized treadmill ergometry. The severity of PTS was analyzed using the Villalta-Scal…

AdultMalemedicine.medical_specialtyAdolescent030204 cardiovascular system & hematologyIliac Vein030218 nuclear medicine & medical imagingPostthrombotic Syndrome03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansRecurrent thrombosisRegistriesAgedRetrospective StudiesAged 80 and overVenous ThrombosisUltrasonography Doppler Duplexbusiness.industryIncidence (epidemiology)Postthrombotic syndromeIncidencePhlebographyMiddle Agedmedicine.diseaseThrombosisMagnetic Resonance ImagingVenous thrombosisTreatment OutcomeCardiologyQuality of LifeFemalesense organsCardiology and Cardiovascular MedicinebusinessVASA. Zeitschrift fur Gefasskrankheiten
researchProduct

Cardiovascular events and intensity of treatment in polycythemia vera.

2013

A b s t r ac t Background Current treatment recommendations for patients with polycythemia vera call for maintaining a hematocrit of less than 45%, but this therapeutic strategy has not been tested in a randomized clinical trial. Methods We randomly assigned 365 adults with JAK2-positive polycythemia vera who were being treated with phlebotomy, hydroxyurea, or both to receive either more intensive treatment (target hematocrit, <45%) (low-hematocrit group) or less intensive treatment (target hematocrit, 45 to 50%) (high-hematocrit group). The primary composite end point was the time until death from cardiovascular causes or major thrombotic events. The secondary end points were cardiovascula…

MaleHematocritRECURRENT THROMBOSISlaw.inventionAged; Antineoplastic Agents; Cardiovascular Diseases; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hydroxyurea; Janus Kinase 2; Male; Middle Aged; Polycythemia Vera; Thrombosis; Hematocrit; Phlebotomy; Medicine (all)LEUKOCYTOSISPolycythemia veraRandomized controlled trialPhlebotomylawhemic and lymphatic diseasesESSENTIAL THROMBOCYTHEMIAClinical endpointHydroxyureaPolycythemia Vera Secondary ProphylaxisESSENTIAL THROMBOCYTHEMIA RECURRENT THROMBOSIS RISK-FACTOR HEMATOCRIT MANAGEMENT LEUKOCYTOSIS PREVENTION DIAGNOSIS EFFICACY WARFARINPolycythemia Veramedicine.diagnostic_testMedicine (all)Hazard ratioGeneral MedicineMiddle AgedCombined Modality TherapyHematocritCardiovascular DiseasesFemalemedicine.medical_specialtyrandomized trial; polycythemia veraAntineoplastic AgentsCardiovascular eventDIAGNOSISWARFARINRISK-FACTORInternal medicineMANAGEMENTmedicineHumansMyelofibrosisAdverse effectAgedbusiness.industryThrombosisPhlebotomyJanus Kinase 2EFFICACYmedicine.diseasePREVENTIONSurgeryPolycythemia Vera Cardiovascular event hematocritSettore MED/15 - MALATTIE DEL SANGUEbusinessFollow-Up Studies
researchProduct

Direct oral anticoagulants for the treatment of pulmonary embolism in patients with renal impairment.

2021

Pulmonary embolism (PE) is associated with adverse outcomes and substantial morbidity and mortality. Patients with PE often have renal impairment because of shared risk factors and close links between the renal and cardiovascular systems. Furthermore, patients with PE and renal impairment are at increased risk of recurrent thrombosis. Therefore, anticoagulation is crucial to treat the acute event, prevent recurrent venous thromboembolism (VTE), and optimize patient outcomes. However, when treated with an anticoagulant, patients with renal impairment also have an elevated risk of bleeding. Direct oral anticoagulants (DOACs) are the first-choice treatment for acute VTE in eligible patients. H…

medicine.medical_specialtymedicine.drug_classAdministration OralHemorrhage030204 cardiovascular system & hematologyurologic and male genital diseases03 medical and health sciences0302 clinical medicineRisk FactorsmedicineHumansIn patientRecurrent thrombosisPatient groupIntensive care medicinebusiness.industryAnticoagulantAnticoagulantsHematologyVenous Thromboembolismmedicine.diseasePulmonary embolismIncreased risk030220 oncology & carcinogenesisRenal physiologybusinessPulmonary EmbolismVenous thromboembolismThrombosis research
researchProduct